Eli Lilly and Co
Change company Symbol lookup
Select an option...
LLY Eli Lilly and Co
SCLXW Scilex Holding Equity Warrants Exp 11th Oct 2027 *W EXP 10/11/2027
GMBL Esports Entertainment Group Inc
CFRX ContraFect Corp
AAL American Airlines Group Inc
NVDA NVIDIA Corp
AMD Advanced Micro Devices Inc
QQQ Invesco QQQ Trust
AAPL Apple Inc
BBBY Bed Bath & Beyond Inc
Go

Health Care : Pharmaceuticals | Large Cap Growth
Company profile

Eli Lilly and Company is engaged in a drug manufacturing business. The Company discovers, develops, manufactures, and markets products in the human pharmaceutical products segment. Its diabetes products include Basaglar, Humalog, Humulin, Jardiance, Trajenta, and Trulicity. Its oncology products consist of Alimta, Cyramza, Erbitux, Retevmo, Tyvyt, and Verzenio. Its immunology products include Olumiant, Baricitinib, and Taltz. Its neuroscience products include Cymbalta, Emgality, and Zyprexa. Its other therapies consist of Bamlanivimab and etesevimab, Bebtelovimab, Cialis, and Forteo. It maintains special business groups to service wholesalers, pharmacy benefit managers, managed care organizations, group purchasing organizations, government and long-term care institutions, hospitals, and certain retail pharmacies. It manufactures and distributes its products through facilities in the United States, including Puerto Rico, and other countries. Its products are sold in about 120 countries.

Closing Price
$348.01
Day's Change
-1.72 (-0.49%)
Bid
--
Ask
--
B/A Size
--
Day's High
352.18
Day's Low
346.73
Volume
(Average)
Volume:
2,576,176

10-day average volume:
2,710,720
2,576,176

Company Profile

Eli Lilly and Company is engaged in a drug manufacturing business. The Company discovers, develops, manufactures, and markets products in the human pharmaceutical products segment. Its diabetes products include Basaglar, Humalog, Humulin, Jardiance, Trajenta, and Trulicity. Its oncology products consist of Alimta, Cyramza, Erbitux, Retevmo, Tyvyt, and Verzenio. Its immunology products include Olumiant, Baricitinib, and Taltz. Its neuroscience products include Cymbalta, Emgality, and Zyprexa. Its other therapies consist of Bamlanivimab and etesevimab, Bebtelovimab, Cialis, and Forteo. It maintains special business groups to service wholesalers, pharmacy benefit managers, managed care organizations, group purchasing organizations, government and long-term care institutions, hospitals, and certain retail pharmacies. It manufactures and distributes its products through facilities in the United States, including Puerto Rico, and other countries. Its products are sold in about 120 countries.

Valuation Ratios

Price/Earnings (TTM)
52.56x
Price/Sales (TTM)
11.36x
Price/Book (MRQ)
33.00x
Price/Cash Flow (TTM)
43.57x
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend

Short Interest

January 2023
Current Month
4.9M
Previous Month
5.6M
Percent of Float
0.52%
Days to Cover
2.2412 Days

Share Information

LLY is in a share class of common stock
Float
948.7M
Shares Outstanding
950.2M
Institutions Holding Shares
3,094
83.15%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in millions.

Cash flow

Values displayed are in millions.

Company Officers

  • David A. RicksPres.
  • Anat AshkenaziCFO
  • Diogo RauSr.VP
  • Daniel M. SkovronskySr.VP
  • Alonzo WeemsSr.VP

Address

Insider Trading

During the most recent quarter, 660 shares were bought, and 1M shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2023. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.